Imagine using stem cells to rebuild the heart following severe heart failure or coronary heart disease. James T. Willerson, MD, President and Medical Director of the Texas Heart Institute at St. Luke’s…
James T. Willerson, MD, President and Medical Director of the Texas Heart Institute at St. Luke’s Episcopal Hospital, addresses a topic of great concern in cardiology today: leakage following aortic…
James T. Willerson, MD, President and Medical Director of the Texas Heart Institute at St. Luke’s Episcopal Hospital, discusses groundbreaking new therapies to cure cardiovascular disease using stem cell technology.…
NEW YORK (Reuters Health) – Ablation of atrial fibrillation by combining the transvenous catheter approach with the thoracoscopic epicardial approach in a single procedure has a high success…
NEW YORK (Reuters Health) – In clinical practice, XIENCE V everolimus-eluting coronary stent is associated with low event rates at one year, according to a large post-marketing study.…
NEW YORK (Reuters Health) – Implantation of a second transcatheter heart valve (THV-in-THV) is effective treatment for failed transcatheter aortic valve replacement (TAVR), according to a report in…
NEW YORK (Reuters Health) – Reperfusion-induced myocardial edema during percutaneous coronary intervention for MI can be attenuated by applying ischemic conditioning at the start of reperfusion, a French…
NEW YORK (Reuters Health) – Treatment with the antianginal drug ranolazine before elective percutaneous coronary intervention (PCI) significantly reduced procedure-related myocardial injury in a small pilot study from…
NEW YORK (Reuters Health) – Compared with unfractionated heparin (UFH) monotherapy, bivalirudin use in patients undergoing percutaneous coronary intervention via the femoral artery is associated with significantly decreased…
NEW YORK (Reuters Health) – Results of a new meta-analysis indicate that all drug-eluting stents (DES) outperform bare metal stents (BMS) over both the short and long term,…